Navigation Links
Valeant to Acquire Polish Dermatology Company
Date:5/8/2009

ALISO VIEJO, Calif., May 8 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) announced that it has acquired EMO-FARM Ltd., a privately held company located in Poland for approximately $28 million. The transaction expands the base for Valeant in Poland into multiple therapeutic categories. EMO-FARM has a strong expertise in topical products and brings with it a portfolio of currently marketed products and additional products under registration. As part of the transaction, Valeant will also acquire a state-of-the-art 13,000 square foot manufacturing plant completed earlier this year that specializes in gels, creams and ointments. Current annualized revenues are approximately $12 million.

"The acquisition of EMO-FARM is consistent with our business plan strategy," stated J. Michael Pearson, chairman and chief executive officer. "We now have a platform from which we can launch various topical products including our dermatology pipeline and become a premier dermatology company in the countries in which we operate The combination of an established portfolio of products, an anti-infective topical compound we plan to launch in 2010, and a cGMP-ready plant that equips us with new manufacturing capabilities, provides us with a solid dermatology opportunity in Poland, and eventually, throughout Central Europe."

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding the future growth in Valeant's European dermatology franchise, the impact of the EMO-FARM Ltd. acquisition on Valeant's business, the timing and potential success of registration and the approval of product candidates. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to our ability to successfully integrate the EMO-FARM assets, risks and uncertainties relating to the clinical development of product candidates, regulatory approval processes, the potential that competitors may bring to market products or treatments that are more commercially attractive than existing or future EMO-FARM products, and other risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the SEC, which factors are incorporated herein by reference. These risks are among the factors that could cause actual results to differ materially from the expectations described in the forward-looking statements and undue reliance should not be placed on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

    Contact:
    Laurie W. Little
    Valeant Pharmaceuticals
    949-461-6002

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
2. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
3. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
4. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
5. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
6. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
7. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
8. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
9. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
10. JLL Announces Extension of Its Offer To Acquire Patheon and Take Up of Deposited Restricted Voting Shares
11. Teikoku Pharma USA Acquires Travanti Pharma Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... MA (PRWEB) , ... February 11, 2016 , ... The ... overpaying for IT services, what questions to ask your IT consultant before signing a ... access to your computer network. , “With companies relying heavily on e-mail and technology, ...
(Date:2/11/2016)... , ... February 11, 2016 , ... As part of ... of the Million Dollar Round Table Foundation (MDRTF), has gifted $10,000 to University of ... Colleen’s Dream Foundation President Billy Cundiff. , “We are honored to support a promising ...
(Date:2/10/2016)... City, California (PRWEB) , ... February 10, 2016 ... ... Imaging Society (WMIS), known as the World Molecular Imaging Congress (WMIC), will be ... theme for the 2016 meeting is “Imaging Biology…Improving Therapy.” The congress will highlight ...
(Date:2/10/2016)... ... 2016 , ... Early this week, Team Iconic at J. Walter Thompson and ... the first global confectionery brand sourced from 100% sustainable cocoa. , The Nestlé Cocoa ... product, through activities that focus on better farming, better lives and better cocoa. In ...
(Date:2/10/2016)... , ... February 10, 2016 ... ... Inc. , a full-service health care communications company offering education, research and ... resource for practitioners and specialists working in infectious diseases. , As the ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 --> ... Gas), and Spectroscopy Market by Industry (Oil & Gas, Petrochemical, ... Paper, Metal & Mining, and Others), And Geography - ... market is expected to grow to USD 3.9 Billion ... 2015 and 2020. Browse 82 market data ...
(Date:2/10/2016)... -- Resolve Therapeutics, LLC, a clinical stage biopharmaceutical company ... of lupus and Sjogrens syndrome, today announced the ... in patients with systemic lupus erythematosus (SLE) with ... --> Data from a multicenter ... RSLV-132 in 32 subjects with SLE demonstrate the ...
(Date:2/10/2016)... -- Urologix, the market leader for in-office minimally invasive ... (BPH), announces new private ownership and is operating as ... industry veteran of more than 20 years, has been ... Plymouth, Minn. The company,s two ... RF Therapy, will continue to be broadly available and ...
Breaking Medicine Technology: